Investment led by Cinctive Co-Founder Richard Schimel underscores institutional confidence in NeOnc’s biotech pipelineCALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") for the purcha ...

Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be presented at WORLDSymposium™ 2026 NOVATO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has resubmitted its Biologics License Application (BLA) seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for p ...

New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II ...

Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is impleme ...

Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidenceIf approved, Rezurock would offer a new treatment option in the EU for adult patients and in children aged 12 years and older in late line chronic GVHD Paris, January 30, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending ...

Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidenceIf approved, Rezurock would offer a new treatment option in the EU for adult patients and in children aged 12 years and older in late line chronic GVHD Paris, January 30, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending ...

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be $41.6 ...

Zai Lab Limited (NASDAQ:ZLAB) ranks among the best high growth Chinese stocks to buy. On January 7, UBS began coverage of Zai Lab Limited (NASDAQ:ZLAB) with a Buy rating and a $35 price target, citing the company’s transition from a China-centric commercial strategy to a global innovation powerhouse. The firm views Zai Lab Limited (NASDAQ:ZLAB) as a distinct biopharma platform poised for long-term global expansion by leveraging its strong China-based business while developing a pipeline of fully owned canc ...

Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy. On January 20, RBC Capital increased Ascendis Pharma A/S (NASDAQ:ASND)’s price target to $250 from $245 while maintaining an Outperform rating on the company. The firm’s improved projection comes after Ascendis Pharma A/S (NASDAQ:ASND) announced major goals for 2026, with the company estimating maintaining launch momentum for Yorvipath with no drop in patient intakes. Ascendis Pharma A/S (NASDAQ:ASND) stated that t ...

Core Viewpoint - POXEL SA has successfully exited judicial reorganisation proceedings, with the recovery plan ratified by the Commercial Court of Lyon, allowing the company to focus on its commercial development and settle its liabilities [1][2][3]. Recovery Plan Key Elements - The recovery plan includes business development, cost structure optimisation, and settlement of outstanding liabilities [4]. - The company aims to establish new partnerships for the commercialisation of Imeglimin in Asia, particularly in China, and promote PXL770 for ADPKD while leveraging the value of PXL065 in HCM [6]. Financial Structure Strengthening - Measures include a €5 million equity line over five years from IRIS, new bond borrowings of €3.75 million from IPF, and a capital increase with maintenance of shareholders' preferred subscription rights [5][6]. - The company plans to convert part of the IPF debt into shares and settle other creditors according to an agreed repayment schedule [6]. Company Overview - POXEL is a clinical stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology, including MASH and rare disorders [8]. - The company’s product pipeline includes PXL065, PXL770, and Imeglimin, with Imeglimin already marketed in Japan through a partnership with Sumitomo Pharma [8].